Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 15/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | APEX1 | P27695 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.40 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4421292 | 0.87 | DPP4 (0.73) | DPP4LMNASMN1; SMN2CYP3A4ADORA3 | |
| SCHEMBL4430115 | 0.83 | DPP4 (0.62) | DPP4CYP3A4ADORA3ADORA2A | |
| SCHEMBL6222236 | 0.80 | SMN1; SMN2 (0.50) | LMNASMN1; SMN2ADORA3ADORA2AAPEX1 | |
| SCHEMBL4423802 | 0.77 | DPP4 (1.00) | DPP4CYP3A4CYP2C19KCNH2DPP8 | |
| SCHEMBL6223940 | 0.76 | DPP4 (0.48) | DPP4LMNASMN1; SMN2ADORA2ADPP8 | |
| SCHEMBL9161207 | 0.74 | LMNA (0.48) | LMNASMN1; SMN2CYP3A4APEX1CYP2C19 | |
| SCHEMBL4417855 | 0.73 | DPP4 (0.76) | DPP4CYP3A4CYP2C19KCNH2DPP8 | |
| SCHEMBL18227141 | 0.72 | BACE1 (0.46) | DPP4LMNASMN1; SMN2ADORA3ADORA2A | |
| SCHEMBL8956069 | 0.71 | LMNA (0.51) | LMNASMN1; SMN2APEX1 | |
| SCHEMBL28160160 | 0.71 | LMNA (0.57) | LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4216197-B2 | — | — | 2009-01-28 | — | — | JP | claimed |
| EP-1476429-B1 | NOVEL PYRIDINE- AND QUINOLINE-DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2005-11-16 | — | — | EP | claimed |
| JP-2005526034-A | — | — | 2005-09-02 | — | — | JP | claimed |
| EP-1476429-A1 | NOVEL PYRIDINE- AND QUINOLINE-DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-17 | — | — | EP | claimed |
| WO-2003068748-A9 | NOVEL PYRIDINE- AND QUINOLINE-DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2004-10-07 | — | — | WO | claimed |
| US-6800650-B2 | FOR THERAPY AND PROPHYLAXIS OF DIABETES, PARTICULARLY NON-INSULIN DEPENDENT DIABETES MELLITUS AND IMPAIRED GLUCOSE TOLERANCE. | HOFFMANN-LA ROCHE INC. | 2004-10-05 | — | — | US | claimed |
| US-20030195188-A1 | Pyridine and quinoline derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2003-10-16 | — | — | US | claimed |
| WO-2003068748-A1 | NOVEL PYRIDINE- AND QUINOLINE-DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-08-21 | — | — | WO | claimed |
| EP-1476429-B1 | NOVEL PYRIDINE- AND QUINOLINE-DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2005-11-16 | — | — | EP | disclosed |
| EP-1476429-A1 | NOVEL PYRIDINE- AND QUINOLINE-DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-17 | — | — | EP | disclosed |
| WO-2003068748-A9 | NOVEL PYRIDINE- AND QUINOLINE-DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2004-10-07 | — | — | WO | disclosed |
| WO-2003068748-A9 | NOVEL PYRIDINE- AND QUINOLINE-DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2004-10-07 | — | — | WO | disclosed |
| US-6800650-B2 | FOR THERAPY AND PROPHYLAXIS OF DIABETES, PARTICULARLY NON-INSULIN DEPENDENT DIABETES MELLITUS AND IMPAIRED GLUCOSE TOLERANCE. | HOFFMANN-LA ROCHE INC. | 2004-10-05 | — | — | US | disclosed |
| US-20030195188-A1 | Pyridine and quinoline derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2003-10-16 | — | — | US | disclosed |
| WO-2003068748-A1 | NOVEL PYRIDINE- AND QUINOLINE-DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195188-A1 | Pyridine and quinoline derivatives | DPP4, DPP3, DPP7 | DPP4 1/4885LMNA 4754/4885SMN1; SMN2 2905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.